Procainamide-Induced Myasthenia-like Weakness in a Patient With Peripheral Neuropathy
- 1 June 1981
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 38 (6) , 378-379
- https://doi.org/10.1001/archneur.1981.00510060080016
Abstract
• Because procainamide hydrochloride (Pronestyl) may block neuromuscular transmission (NMT), this drug is contraindicated in cases of myasthenia gravis. Reduction of the safety factor of NMT is also seen in other conditions, including peripheral neuropathies. A patient with uremic peripheral neuropathy in whom myasthenia-like weakness developed during procainamide therapy is described. Procainamide should be given with caution in cases of peripheral neuropathies in which there may be a reduction of the safety factor of NMT.This publication has 10 references indexed in Scilit:
- Disorders of Neuromuscular TransmissionPublished by Oxford University Press (OUP) ,2008
- Disorders of Neuromuscular Transmission Caused by DrugsNew England Journal of Medicine, 1979
- Amyotrophic Lateral SclerosisArchives of Neurology, 1979
- Double‐Step nerve stimulation test for myasthenic block: Sensitization of postactivation exhaustion by ischemiaAnnals of Neurology, 1977
- ELECTRICAL TESTING IN MYASTHENIA GRAVIS*Annals of the New York Academy of Sciences, 1971
- Procainamide--a Hazard in Myasthenia GravisArchives of Neurology, 1965
- EFFECTS OF CENTRAL DEPRESSANT DRUGS UPON ACETYLCHOLINE RELEASEBritish Journal of Pharmacology and Chemotherapy, 1964
- THE GANGLION BLOCKING ACTION OF PROCAINAMIDEBritish Journal of Pharmacology and Chemotherapy, 1964
- THE TREATMENT OF MYOTONIA: A CONTROLLED CLINICAL TRIALBrain, 1959
- ELECTROMYOGRAPHIC STUDY OF DEFECTS OF NEUROMUSCULAR TRANSMISSION IN HUMAN POLIOMYELITISArchives of Neurology & Psychiatry, 1948